Expression and significance of Gli1 in molecular subtypes of breast cancer

PDF(712 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2012, Vol. 23 ›› Issue (10) : 862-865.

LV Xiasheng^¹,DU Zheming^²,ZENG Peng^²,LI Liang^¹,and HU Wei^³. ¹. Medical Department,². the First Department of Surgery,Jiangxi Provincial Corps Hospital of Armed Police Forces,Nanchang ³³⁰⁰³⁰,China; ³. Department of Breast Surgery,Changhai Hospital,SMMU,Shanghai ²⁰⁰⁴³³,China

Author information +

History +

Abstract

Objective To study the relationship between the Hedgehog signaling pathways’ transcription factor Gli1 and molecular markers of breast cancer and to probe its expression and significance in molecular subtypes of breast cancer. Methods Envison immunohistochemical method was used to detect the expression of Gli1 in 90 samples of breast cancer. The relationship between Gli1 and the expression of ER, HER-2 was analyzed. The expression of Gli1 in different molecular subtypes and its significance were discussed. Results The expression of Gli1 and ER were found to be negatively correlated. No significant correlation between Gli1 and HER-2 was exhibited. There was no difference between luminal A, luminal B and HER2 overexpression or between luminal B, HER-2 overexpression and basal-like subtypes (P>0.05). The positive rate of Glil in the basal-like subtype was higher than in luminal A subtype; the difference was statistically significant (P

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LV Xiasheng,DU Zheming,ZENG Peng,LI Liang,and HU Wei. . Medical Department,. the First Department of Surgery,Jiangxi Provincial Corps Hospital of Armed Police Forces,Nanchang,China; . Department of Breast Surgery,Changhai Hospital,SMMU,Shanghai,China. Expression and significance of Gli1 in molecular subtypes of breast cancer[J]. Medical Journal of the Chinese People Armed Police Forces. 2012, 23(10): 862-865

References

［1］邵志敏，余科达. 乳腺外科发展趋势［J］.中国普外基础与临床杂志，2007，14（3）：252-254.

［2］ Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours［J］. Nature, 2000, 406(67): 747-752.

［3］ Berman D M, Karhadkar S S, Maitra A，et al. Widespread requirement for Hedgehog ligand Stimulation in growth of digestive tract tumours［J］. Nature, 2003, 425(69): 846-851.

［4］ Feldman I,Feldman G M, Mobarak C, et al. Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha［J］. Am J Obstet Gynecol, 2007,196:394.e1-11.

［5］ Zhou Y,Eppenberger-Castori S,Eppenberger U, et al.The NFkappaB pathway and endocrine-resistant breast cancer［J］.Endocr Relat Cancer,2005,12(Suppl 1):S37-S46.

［6］ Naksshatri H,Bhat-Nakshatri P, Martin D A, et al.Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth［J］.Mol Cell Biol,1997,17:3629-3639.

［7］ Nielsen T O,Hsu F D,Jensen K, et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma［J］. Clin Cancer Res，2004,10(16):5367-5374.

［8］ Yu K, Lee C H, Tan P H, et al. Conservation of breast cancer moleullar subtypes and stranscriptional patterns of tumor progression across distinct ethnic populations［J］. Clin Cancer Res, 2004,10(16):5508-5517.

［9］ Carey L A, Perou C M, Livasy C A, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study［J］. JAMA, 2006, 295(21): 2492-2502.

［10］ Kubo M, Nakamura M, Tasaki A, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer［J］. Cancer Res, 2004, 64(17):6071-6074.

［11］崔巍. Sonic hedgehog在乳腺癌中的表达及其表达变化的调节机制［D］. 沈阳：中国医科大学, 2009.

［12］ Zhao J, Chen G, Cao D, et al. Expression of Gli1 correlates with the transition of breast cancer cells to estrogen-independent growth［J］. Breast Cancer Res Treat, 2010, 119(1): 39-51.

［13］赵洁莹, 陈欢, 王雁, 等. 雌激素受体α在乳腺癌细胞中对Gli1转录活性和表达的影响［J］. 第二军医大学学报, 2009, 30(11): 1221-1224.

［14］ Ihemelandu C U, Leffall L D, Dewitty R L, et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome［J］. Ann Surg Oncol, 2007, 14(10): 2994-3003.

［15］ Bauer K R, Brown M, Cress R D, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry［J］. Cancer, 2007, 109(9): 1721-1728.

［16］ Smith I, Procter M, Gelber R D, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial［J］. Lancet, 2007, 369(9555): 29-36.

［17］ Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer［J］. N Engl J Med, 2005, 353(16): 1659-1672.